Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

17.82 -0.04 (-0.22%)
Delayed Quote Updated: 12:53 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
News headline image
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. ↗
One of J&J's investments stands head-and-shoulders above the rest. 
Via The Motley Fool
News headline image
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda (TAK) Q1 2026 Earnings Call Transcript ↗
New product launches surge 22.6% as Takeda readies three major launches. 
Via The Motley Fool
Topics Earnings
News headline image
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Pharmaceutical Q1 Earnings Call Highlights ↗
Takeda Pharmaceutical (NYSE:TAK) said its first-quarter fiscal 2026 results were in line with its full-year outlook as growth from core brands and newer products largely offset expected declines in its... 
Via MarketBeat
Topics Earnings
News headline image
Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda
From Hagens Berman
Via Business Wire
News headline image
Takeda Pharmaceutical Q4 Earnings Call Highlights ↗
Takeda Pharmaceutical (NYSE:TAK) reported fiscal 2025 results that management described as solid despite pressure from generic competition to VYVANSE, while outlining a transition plan built around... 
Via MarketBeat
Topics Earnings
News headline image
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Novavax (NVAX) Q2 2025 Earnings Transcript ↗
Novavax (NVAX) Q2 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Why Did Axsome Therapeutics Stock Hit Another Record High Today? ↗
Investors think a new addition to the biotech's pipeline could be the next catalyst. 
Via The Motley Fool
News headline image
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’
On March 31, 2026, Eli Lilly and Company (NYSE:LLY) sent shockwaves through the biotechnology sector by announcing a definitive agreement to acquire Centessa Pharmaceuticals (Nasdaq:CNTA) for a total... 
Via MarketMinute
News headline image
The Orexin Gold Rush: Deep Dive into Eli Lilly’s $7.8 Billion Acquisition of Centessa Pharmaceuticals
Today, March 31, 2026, the biotechnology landscape has been fundamentally reshaped. Eli Lilly and Company (NYSE: LLY) has officially announced a definitive agreement to acquire Centessa Pharmaceuticals... 
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
On March 25, 2026, the landscape of neurodegenerative medicine underwent a seismic shift. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics (NASDAQ: DNLI)... 
Via Finterra
Topics Economy Initial Public Offering
News headline image
The Great Resurgence: A Deep Dive into Grifols S.A. (GRFS) in 2026
As of March 25, 2026, Grifols S.A. (NASDAQ: GRFS) stands at a pivotal crossroads in its century-long history. Once the undisputed champion of the European healthcare sector, the Spanish plasma giant... 
Via Finterra
Topics Bankruptcy Economy Lawsuit
News headline image
The Great Unbundling: How AI’s Insatiable Hunger is Driving a Corporate Divestiture Gold Rush
As of March 18, 2026, the corporate landscape has undergone a radical transformation. The era of the sprawling global conglomerate, once the gold standard of industrial stability, is rapidly giving way... 
Via MarketMinute
Topics Artificial Intelligence Economy
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.